Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria
Open Access
- 1 August 1985
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 28 (2), 308-310
- https://doi.org/10.1128/aac.28.2.308
Abstract
Ciprofloxacin was administered orally to 48 patients with 24 Pseudomonas aeruginosa infections and 13 other infections caused by cephalothin-resistant gram-negative bacilli. The types of infections treated included those of skin or skin structure, bone, urinary tract, and respiratory tract. In 83% of P. aeruginosa infections, a favorable clinical outcome occurred, compared with 85% for all infections. Failure to achieve a cure correlated with the emergence of resistant P. aeruginosa and Acinetobacter calcoaceticus strains in four instances and superinfection with Candida (two cases) and Streptococcus (two cases) species. Therapy was discontinued in three patients because of the development of nausea. Ciprofloxacin appears to be safe and effective in the therapy of infections caused by resistant gram-negative bacilli.This publication has 10 references indexed in Scilit:
- A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactamEuropean Journal of Clinical Microbiology & Infectious Diseases, 1984
- In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasiiAntimicrobial Agents and Chemotherapy, 1984
- Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organismsAntimicrobial Agents and Chemotherapy, 1983
- Piperacillin Therapy for Pseudomonas InfectionsSouthern Medical Journal, 1983
- In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1983
- Ceftazidime in patients with pseudomonas infectionsJournal of Antimicrobial Chemotherapy, 1983
- Clinical experience with Moxalactam in the treatment of pseudomonal and nonpseudomonal infectionsAntimicrobial Agents and Chemotherapy, 1982
- Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapyAntimicrobial Agents and Chemotherapy, 1981
- Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinical relapseAntimicrobial Agents and Chemotherapy, 1980
- Tobramycin Sulfate: A Summary of Worldwide Experience from Clinical TrialsThe Journal of Infectious Diseases, 1976